When does the CEO transition take place, and what are the new CEOs compensation details?

The CEO transition will occur on July 1, 2024. Robert A. Michael will assume the CEO role and will receive an annual base salary of $1,700,000. He will also be eligible for an annual bonus with a target of 150% of his base salary, contingent on performance targets.

What will Richard A. Gonzalez's role and compensation be after the CEO transition?

Richard A. Gonzalez will transition to the role of Executive Chairman of the Board, effective July 1, 2024. His compensation as Executive Chairman will include an annual base salary of $1,500,000 and a target bonus of 140% of his base salary, subject to performance targets.

What were the results of the advisory vote on executive compensation (Say on Pay)?

The advisory vote on the compensation of AbbVie's named executive officers received strong support, with a significant majority of stockholders voting for the proposal. Additionally, stockholders voted to hold these advisory votes on an annual basis going forward.

Were there any significant proposals that were not approved by stockholders?

Yes, several proposals did not receive majority approval. This includes the management proposal to amend the certificate of incorporation to eliminate supermajority voting, a stockholder proposal to implement simple majority voting, a stockholder proposal to issue an annual report on lobbying, and a stockholder proposal to issue an annual report on the patent process.

ABBV 8-K: Leadership Changes & Shareholder Matters

Summary

This 8-K filing from AbbVie Inc. (ABBV) serves as an amendment and provides crucial updates regarding executive leadership and the outcomes of its 2024 Annual Meeting of Stockholders. The most significant development is the confirmation and detailing of Robert A. Michael's compensation package as he prepares to succeed Richard A. Gonzalez as CEO on July 1, 2024. Mr. Michael will receive a base salary of $1,700,000 and a target bonus of 150% of his base salary. Concurrently, Mr. Gonzalez will transition to Executive Chairman of the Board, with a base salary of $1,500,000 and a target bonus of 140% of his base salary. Furthermore, the filing details the results of the stockholder votes from the May 3, 2024 Annual Meeting. Key outcomes include the election of Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and strong advisory approval for executive compensation. Notably, stockholders voted to hold future "say on pay" votes on an annual basis. However, several management and stockholder proposals, including the elimination of supermajority voting and proposals related to lobbying and patent process reports, did not receive majority approval from stockholders.

Key Highlights

1Robert A. Michael's compensation package as incoming CEO (effective July 1, 2024) has been finalized, including a $1.7M base salary and a 150% target bonus.
2Richard A. Gonzalez's compensation as Executive Chairman has been set at $1.5M base salary with a 140% target bonus.
3Stockholders elected Class III directors, including Richard A. Gonzalez, Roxanne S. Austin, Susan E. Quaggin, Rebecca B. Roberts, and Glenn F. Tilton.
4Ernst & Young LLP was ratified as AbbVie's independent registered public accounting firm for 2024.
5An advisory vote on executive compensation (Say on Pay) received strong approval from stockholders.
6Stockholders approved holding future Say on Pay votes on an annual basis.
7Several management and stockholder proposals, including the elimination of supermajority voting and reporting on lobbying and patent processes, did not pass.

AbbVie Inc. 8-K/A Report, Executive Changes (May 8, 2024)

Summary

Key Highlights

Frequently Asked Questions